Abbott Labs (ABT) PT Raised to $145 at Jefferies
Jefferies analyst Raj Denhoy raised the price target on Abbott Labs (NYSE: ABT) to $145.00 (from $135.00) while maintaining a Buy rating following earnings.
The analyst commented, "Key post call datapoints: 1) COVID testing still elevated with $1-$1.4bn baked into 4Q guide, 2) screening versus symptomatic testing appears somewhat durable, 3) Amulet US adoption trending ahead of internal expectations with buy-in across 40% of targeted accounts, 4) T2 adoption (II and non-insulin) drives Libre to another new high; 5) Aiming for well north of 5% share in TAVR w/Portico overtime. Raising numbers and PT to $145 (prior $135) keeping us at Buy."